A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses
Public ClinicalTrials.gov record NCT02120898. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Imiquimod Cream, 2.5% and Zyclara® (Imiquimod) Cream, 2.5% in Subjects With Actinic Keratoses
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study it so compare the safety and efficacy profiles of a generic imiquimod 2.5% cream to the reference listed Zyclara® (imiquimod) cream in the treatment of actinic keratosis (AK).
Study identification
- NCT ID
- NCT02120898
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 467 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 9, 2013
- Primary completion
- Apr 29, 2014
- Completion
- Apr 29, 2014
- Last update posted
- Dec 12, 2019
2013 – 2014
United States locations
- U.S. sites
- 27
- U.S. states
- 15
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 1 | Birmingham | Alabama | 35025 | — |
| Site 10 | Fremont | California | 94538 | — |
| Site 8 | Los Angeles | California | 90045 | — |
| Site 24 | Denver | Colorado | 80220 | — |
| Site 28 | Boca Raton | Florida | 33486 | — |
| Site 26 | Brandon | Florida | 33511 | — |
| Site 27 | Brandon | Florida | 33511 | — |
| Site 21 | Boise | Idaho | 83704 | — |
| Site 3 | Arlington Heights | Illinois | 60005 | — |
| Site 17 | Champaign | Illinois | 61820 | — |
| Site 7 | Carmel | Indiana | 46032 | — |
| Site 15 | Indianapolis | Indiana | 46256 | — |
| Site 22 | Plainfield | Indiana | 46168 | — |
| Site 23 | South Bend | Indiana | 46617 | — |
| Site 16 | Clinton Township | Michigan | 48038 | — |
| Site 13 | Fridley | Minnesota | 55432 | — |
| Site 9 | Albuquerque | New Mexico | 87106 | — |
| Site 4 | High Point | North Carolina | 27262 | — |
| Site 11 | Wilmington | North Carolina | 28403 | — |
| Site 18 | Winston-Salem | North Carolina | 27103 | — |
| Site 25 | Portland | Oregon | 97223 | — |
| Site 20 | Fountain Inn | South Carolina | 29644 | — |
| Site 6 | Knoxville | Tennessee | 37917 | — |
| Site 5 | Nashville | Tennessee | 37203 | — |
| Site 14 | Austin | Texas | 78759 | — |
| Site 12 | College Station | Texas | 77845 | — |
| Site 2 | Houston | Texas | 77056 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02120898, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 12, 2019 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02120898 live on ClinicalTrials.gov.